Evolent Health (NYSE:EVH) reported Q1 EPS of ($0.06), $0.06 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $297 million versus the consensus estimate of $286.77 million.
GUIDANCE:
Evolent Health sees Q2 2022 revenue of $290-305 million, versus the consensus of $285 million.
Evolent Health sees FY2022 revenue of $1.16-1.21 billion, versus the consensus of $1.16 billion.